Targeting MET Dysregulation in Cancer.
Targeting MET Dysregulation in Cancer.
复制标题
DOI：
10.1158/2159-8290.cd-19-1446
复制
发表时间：
2020-07
期刊：
影响因子：
28.2
通讯作者：
Awad MM
中科院分区：
文献类型：
--
作者：
Recondo G;Che J;Jänne PA;Awad MM
异常MET信号传导可以通过多种分子机制（包括MET基因扩增、突变、重排和过表达）驱动几种癌症类型中的肿瘤发生。最近，生物标志物发现和测试的改进使得能够选择患有MET依赖性癌症的患者进行有效，特异性和新型MET靶向疗法的治疗。我们回顾了已知的激活MET的肿瘤学过程，讨论了MET依赖性恶性肿瘤的治疗策略，并强调了这些癌症中获得性耐药的新挑战。
Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of molecular mechanisms including MET gene amplification, mutation, rearrangement, and overexpression. Improvements in biomarker discovery and testing have more recently enabled the selection of patients with MET-dependent cancers for treatment with potent, specific, and novel MET-targeting therapies. We review the known oncologic processes that activate MET, discuss therapeutic strategies for MET-dependent malignancies, and highlight emerging challenges in acquired drug resistance in these cancers.